Acceleron Pharma (XLRN) Tops Q4 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Acceleron Pharma (XLRN) Tops Q4 EPS by 4c

Acceleron Reports Fourth Quarter and Year Ended 2016 Operational and Financial Results

March 1, 2017 7:02 AM EST

- Luspatercept Phase 3 trials to complete enrollment in both the MDS (MEDALIST) and beta-thalassemia (BELIEVE) trials in 2H 2017 -

- Presented data from five abstracts on luspatercept and sotatercept at the American Society of Hematology Annual Meeting in December -

- Treated first patient in ACE-083 Phase 2 study for facioscapulohumeral muscular dystrophy -

- Outlined plans to initiate several new clinical trials in 2017 -

- Maintained strong balance sheet with $234.4 million in cash and investments to fund projected operating requirements into... More